Online citations, reference lists, and bibliographies.

Prognostic Indicators In Peritoneal Carcinomatosis From Gastrointestinal Cancer

Rhonda L Harmon, P. Sugarbaker
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Peritoneal carcinomatosis from gastrointestinal cancer has new treatment options for surgical management. The approach uses cytoreductive surgery which combines peritonectomy and visceral resection in an effort to remove all visible cancer within the abdomen and pelvis. Then the peritoneal cavity is flooded with chemotherapy solution in an attempt to eradicate residual disease. In order to select patients for this approach the quantitative prognostic indicators for carcinomatosis were reviewed, compared and contrasted. Prognostic indicators to be used to select patients for this aggressive approach at the initiation of surgery and after completion of cytoreduction were studied. Four quantitative assessments to be used at the time of abdominal exploration were the Gilly staging, Japanese gastric cancer P score, peritoneal cancer index (PCI), and the simplified peritoneal cancer index (SPCI). All have value with the PCI being the most validated and most precise. Preoperative assessments include the tumor histopathology and the prior surgical score. The completeness of cytoreduction score is an assessment of residual disease after a maximal surgical effort. An opportunity for long-term survival following treatment for carcinomatosis requires a complete cytoreduction in all reports for gastrointestinal cancer. Quantitative prognostic indicators need to be knowledgeably employed when patients with carcinomatosis are being treated. Improved patient selection with greater benefit and reduced morbidity and mortality should result.
This paper references
10.1007/s002800051093
Successful management of microscopic residual disease in large bowel cancer
P. Sugarbaker (1999)
by complete resection and intraperitoneal chemotherapy
PH Sugarbaker (2001)
10.1016/S0959-8049(01)00058-2
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
A. Witkamp (2001)
10.1002/JSO.20013
Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
V. Verwaal (2004)
Intraperitoneal chem - ohyperthermia with mitomycin C for digestive tract
AC Beaujard
Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary.
B. M. Ronnett (1997)
10.1007/978-1-4613-1247-5
Peritoneal Carcinomatosis: Principles of Management
P. Sugarbaker (1996)
10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O
Peritoneal carcinomatosis from non‐gynecologic malignancies
B. Sadeghi (2000)
Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery.
P. Jacquet (1995)
10.1097/00000658-199502000-00002
Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy
P. Sugarbaker (1995)
10.1200/JCO.2004.10.012
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
O. Glehen (2004)
Zoetmulder FAN: Toxicity of cytoreduction and hyperthermic intra-peritoneal chemotherapy
VJ Verwaal (2004)
10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V
Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors
D. Chu (1989)
10.1046/J.1365-2168.2002.02274.X
Peritoneal carcinomatosis from colorectal cancer
D. Jayne (2002)
10.1200/JCO.2003.06.139
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.
O. Glehen (2003)
Second-look surgery after cytoreductive and intraperitoneal chemotherapy for
A Gomez-Portilla
10.1007/s002689900560
Second-look Surgery after Cytoreduction and Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer: Analysis of Prognostic Features
A. Portilla (1999)
Toxicity of cytoreduction and hyperthermic intraperitoneal chemotherapy
VJ Verwaal (2004)
10.1200/JCO.2003.04.187
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
V. Verwaal (2003)
10.1053/EJSO.2002.1380
Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer.
A. Tentes (2003)
10.1002/1097-0142(20000601)88:11<2512::AID-CNCR12>3.0.CO;2-J
Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis
A. Beaujard (2000)
Peritoneal Carcinomatosis in non gynecologic malignancy
DZ Chu (1989)
10.1007/978-1-4613-1247-5_23
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.
P. Jacquet (1996)
10.1007/s10434-999-0727-7
Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy
P. Sugarbaker (1999)
10.1002/1097-0142(19930901)72:5<1631::AID-CNCR2820720523>3.0.CO;2-I
Evaluation of computed tomography in patients with peritoneal carcinomatosis
P. Jacquet (1993)
10.1016/S0039-6060(96)80145-0
Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination.
Y. Yonemura (1996)
10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy
D. Elias (2001)
10.1007/s004230050246
Management of peritoneal-surface malignancy: the surgeon’s role
P. Sugarbaker (1999)
patients with peritoneal carcinomatosis
O Glehen (2000)
Seow-Choen F: Peritoneal carcinomatosis from colorectal cancer
Dg Jayne (2002)



This paper is referenced by
10.1007/s00423-013-1144-8
Surgical treatment of peritoneal carcinomatosis: current treatment modalities
Yakup Kulu (2013)
10.1016/j.ejso.2014.03.001
Cytoreductive surgery plus perioperative intraperitoneal chemotherapy in pseudomyxoma peritonei: aspects of the learning curve.
Hanna Andréasson (2014)
10.3748/wjg.v20.i39.14371
Peritoneal carcinomatosis of gastrointestinal tumors: where are we now?
C. Terzi (2014)
10.1016/S1283-081X(15)70033-0
Cáncer de ovario: diagnóstico, evaluación y estrategia terapéutica
Adrien Le Roch (2015)
10.11648/j.ijcocr.20170204.11
Peritoneal Cancer Indexes in Ovarian Carcinomatosis: Correlation Between CT and Intraoperative Results and Survival
Lombardo Galera Maria Sagrario (2017)
Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
D. Baratti (2008)
10.1016/j.jpedsurg.2010.02.034
Novel treatment for desmoplastic small round cell tumor: hyperthermic intraperitoneal perfusion.
A. Hayes-Jordan (2010)
10.1186/1477-7819-12-270
Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
T. Jayakrishnan (2014)
10.1245/s10434-009-0387-7
18F-FDG-PET/CT to Select Patients with Peritoneal Carcinomatosis for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
C. Pfannenberg (2009)
10.1213/ANE.0b013e3182860fff
An Overview of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for the Anesthesiologist
C. Webb (2013)
10.24931/2413-9432-2016-5-3-9-18
INTRAOPERATIVE FLUORESCENCE DIAGNOSIS OF PERITONEAL DISSEMINATION IN PATIENTS WITH GASTRIC CANCER
E. A. Suleymanov (2016)
ases and foundations of the treatment of peritoneal arcinomatosis : Review article
F. Castro-Mestaa (2016)
10.3802/jgo.2019.30.e3
Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study
Y. Lee (2019)
10.21037/jgo.2018.04.05
Outcome and factors associated with aborted cytoreduction for peritoneal carcinomatosis.
Whitney Guerrero (2018)
10.1016/j.ejrad.2011.01.033
Ultrasonography findings and tumour quantification in patients with pseudomyxoma peritonei.
Johan Krause (2012)
10.1002/jso.25967
Outcomes of neoadjuvant chemotherapy before CRS-HIPEC for patients with appendiceal cancer.
J C Chen (2020)
10.1002/JSO.20837
Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis.
A. Capone (2007)
10.1055/a-1018-2516
S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL
M. Moehler (2019)
10.1002/cncr.32867
The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms
Claire Hoppenot (2020)
10.1016/j.gore.2020.100610
Concurrent hysterectomy and bilateral salpingo-oophorectomy during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for non-gynecologic cancers
McKayla J Riggs (2020)
10.1245/s10434-014-4329-7
Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer
Khayal Gasimli (2014)
10.20892/j.issn.2095-3941.2017.0162
Diagnostic value of whole-body MRI with diffusion-weighted sequence for detection of peritoneal metastases in colorectal malignancy
Huan Zhang (2018)
Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer?
N. Cigdem Arslan (2018)
10.1016/j.ijrobp.2012.09.005
Reduced toxicity with intensity modulated radiation therapy (IMRT) for desmoplastic small round cell tumor (DSRCT): an update on the whole abdominopelvic radiation therapy (WAP-RT) experience.
N. Desai (2013)
10.1111/J.1525-1438.2006.00580.X
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
10.1016/j.soc.2012.07.005
Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging, and treatment.
M. Valle (2012)
10.18632/oncotarget.16480
Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy
James McMullen (2017)
10.21474/IJAR01/936
Peritoneal Carcinomatosis: Pictorial Review of Computed Tomography Findings.
Dr.S.SubhaschandraSingh. (2016)
10.1016/j.ajpath.2010.12.019
Netrin-4 delays colorectal cancer carcinomatosis by inhibiting tumor angiogenesis.
C. Eveno (2011)
10.1002/jso.23446
Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit?
Justin D. Rivard (2014)
Aspectos relevantes en la atención médica oncológica en el Hospital Regional de Alta Especialidad de Oaxaca
Rolando García-Matus (2013)
10.1016/j.jconrel.2014.01.012
Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.
Jie Wang (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar